Means and methods for treating subjects with her2 and her3 positive cancer
WO2021034194A2
Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor.
US2021054049A1
Variant domains for multimerizing proteins and separation thereof
TW202039578A
Cd3 binding molecules
WO2020167122A1
Producing compositions comprising two or more antibodies.
WO2020167123A1
Combinations of binding moieties that bind egfr, her2 and her3.
TW202039577A
Truncated multivalent multimers
WO2020141973A1
Mixed binding domains
WO2020130829A1
Clec12axcd3 bispecific antibodies and methods for the treatment of disease
EP3772518A1
Modified human variable domains
SG11202009036YA
Multivalent antibody
US2020384084A1
Use of bispecific antibody and il-15 for combination therapy
CN111094351A
Antibodies binding to EGFR and cMET
TW201920657A
Antibodies that modulate a biological activity expressed by a cell
EP3649154A1
Binding molecules that modulate a biological activity expressed by a cell
WO2019009728A1
Antibodies that modulate a biological activity expressed by a cell
EP3625264A1
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
EP3600411A1
Antibodies for the treatment of erbb-2/erbb-3 positive tumors
AU2018246872A1
ErbB-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbB-3, for treatment of an individual with an erbB-2, erbB-2/erbB-3 positive tumour
CN110650752A
ErbB-2 and ErbB3 binding bispecific antibodies for treating cells with NRG1 fusion gene
